The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S.
The drug was approved for use in adults and children 12 and older and is a once-daily oral medication that targets neutrophilic inflammation, a key driver of the disease, according to an Aug. 12 news release from the drugmaker.
The approval is based on results from phase 2 and phase 3 clinical trials, both of which showed significant reductions in disease exacerbations and improvements in lung function. In the phase 3 trial, the drug reduced the annual rate of exacerbations by over 20% compared to the placebo. The drug is now available in the U.S. for prescription use, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
